Nuvo Pharmaceuticals Inc
TSX:MRV
Nuvo Pharmaceuticals Inc
TSX:MRV
Price:
1.35
CAD
Market Closed
Market Cap:
CA$15.4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Nuvo Pharmaceuticals Inc
TSX:MRV
|
CA |
|
S
|
Socovesa SA
SGO:SOCOVESA
|
CL |
|
Perdana Karya Perkasa Tbk PT
IDX:PKPK
|
ID |
|
N
|
Nexeon Medsystems Inc
OTC:NXNN
|
US |
|
Furukawa Co Ltd
TSE:5715
|
JP |
|
F
|
Forbidden Spirits Distilling Corp
XTSX:VDKA
|
CA |
|
Dyaco International Inc
TWSE:1598
|
TW |
|
U
|
Utron Ltd
TASE:UTRN
|
IL |
|
Ctp NV
AEX:CTPNV
|
NL |
|
I
|
IONOS Group SE
XETRA:IOS
|
DE |
|
ViewRay Inc
OTC:VRAYQ
|
US |
|
C
|
Cokyvina JSC
VN:CKV
|
VN |
|
S
|
Spire Inc
SWB:LGR
|
US |
|
Leonardo SpA
OTC:FINMF
|
IT |
|
Enensys Technologies SA
PAR:ALNN6
|
FR |
|
Calin Technology Co Ltd
TWSE:4976
|
TW |
Balance Sheet
Balance Sheet Decomposition
Nuvo Pharmaceuticals Inc
Nuvo Pharmaceuticals Inc
Balance Sheet Decomposition is not available for
Nuvo Pharmaceuticals Inc
Nuvo Pharmaceuticals Inc
Balance Sheet
Nuvo Pharmaceuticals Inc
Nuvo Pharmaceuticals Inc
Currency: CAD
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
12
|
13
|
48
|
49
|
10
|
8
|
28
|
23
|
24
|
31
|
|
| Cash Equivalents |
12
|
13
|
48
|
49
|
10
|
8
|
28
|
23
|
24
|
31
|
|
| Short-Term Investments |
0
|
0
|
10
|
0
|
8
|
2
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
4
|
5
|
4
|
6
|
3
|
2
|
14
|
15
|
8
|
9
|
|
| Accounts Receivables |
4
|
4
|
3
|
6
|
2
|
2
|
14
|
15
|
8
|
9
|
|
| Other Receivables |
0
|
0
|
1
|
1
|
0
|
0
|
1
|
1
|
0
|
0
|
|
| Inventory |
1
|
1
|
2
|
2
|
4
|
3
|
14
|
8
|
10
|
9
|
|
| Other Current Assets |
1
|
0
|
0
|
1
|
1
|
0
|
2
|
1
|
2
|
2
|
|
| Total Current Assets |
18
|
18
|
64
|
58
|
25
|
15
|
58
|
47
|
44
|
51
|
|
| PP&E Net |
2
|
1
|
1
|
1
|
1
|
4
|
5
|
5
|
5
|
4
|
|
| PP&E Gross |
2
|
1
|
1
|
1
|
1
|
4
|
5
|
5
|
5
|
4
|
|
| Accumulated Depreciation |
5
|
6
|
6
|
6
|
4
|
4
|
4
|
5
|
6
|
5
|
|
| Intangible Assets |
9
|
2
|
0
|
0
|
0
|
9
|
95
|
84
|
74
|
62
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
1
|
28
|
28
|
27
|
14
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
18
|
0
|
3
|
0
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
1
|
28
|
28
|
27
|
14
|
|
| Total Assets |
29
N/A
|
22
-24%
|
65
+201%
|
59
-9%
|
27
-55%
|
30
+13%
|
204
+584%
|
163
-20%
|
152
-7%
|
130
-14%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
3
|
4
|
9
|
9
|
4
|
3
|
20
|
10
|
8
|
11
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
4
|
0
|
0
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
2
|
2
|
0
|
0
|
0
|
0
|
7
|
18
|
12
|
13
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
1
|
|
| Total Current Liabilities |
6
|
6
|
9
|
9
|
4
|
4
|
31
|
28
|
22
|
25
|
|
| Long-Term Debt |
1
|
3
|
0
|
0
|
0
|
0
|
117
|
105
|
93
|
85
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
35
|
5
|
17
|
29
|
|
| Total Liabilities |
7
N/A
|
9
+34%
|
10
+1%
|
9
-1%
|
4
-61%
|
5
+30%
|
184
+3 727%
|
139
-24%
|
131
-5%
|
142
+8%
|
|
| Equity | |||||||||||
| Common Stock |
229
|
229
|
234
|
235
|
185
|
185
|
185
|
185
|
185
|
185
|
|
| Retained Earnings |
221
|
232
|
193
|
200
|
177
|
175
|
180
|
177
|
181
|
213
|
|
| Additional Paid In Capital |
14
|
14
|
14
|
14
|
14
|
15
|
15
|
16
|
16
|
16
|
|
| Other Equity |
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
22
N/A
|
12
-43%
|
56
+357%
|
50
-11%
|
23
-54%
|
25
+10%
|
21
-18%
|
24
+16%
|
20
-15%
|
11
N/A
|
|
| Total Liabilities & Equity |
29
N/A
|
22
-24%
|
65
+201%
|
59
-9%
|
27
-55%
|
30
+13%
|
204
+584%
|
163
-20%
|
152
-7%
|
130
-14%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
9
|
9
|
11
|
11
|
12
|
12
|
11
|
11
|
11
|
11
|
|
Switch to:
Switch to:
See Also
Discover More
